07:00 , Aug 15, 2011 |  BioCentury  |  Product Development

Locking in lebrikizumab

In the race to treat asthma by blocking IL-13, Genentech Inc. now has positive Phase II data and a biomarker for responders to lebrikizumab in severe asthma patients. Next up is data from MedImmune LLC...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Clinical News

Aerovant: Phase IIb data

In the double-blind, dose-ranging, U.S. and European Phase IIb AeroTrial trial in 534 patients inadequately controlled with inhaled corticosteroids and long-acting beta-2 adrenergic agonists (LABAs), all 3 doses of inhaled Aerovant missed the primary endpoint...
23:27 , Jun 8, 2010 |  BC Extra  |  Clinical News

Aerovant misses asthma endpoint

Aerovance Inc. (Berkeley, Calif.) said all three doses of inhaled Aerovant missed the primary endpoint of significantly reducing the incidence of asthma exacerbations vs. placebo in the Phase IIb AeroTrial to treat moderate to severe...
08:00 , Feb 8, 2010 |  BioCentury  |  Emerging Company Profile

Altair: Breathing easier with antisense

Several compounds in development to treat asthma have been designed to modify the underlying disease by inhibiting or disrupting the inflammatory activity of the cytokines IL-4 and IL-13. So far, compounds targeting one or the...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Aerovant: Completed Phase IIb enrollment

Aerovance completed enrollment of about 540 patients in the double-blind, placebo-controlled, U.S. and European Phase llb AeroTrial trial evaluating 1, 3 or 10 mg inhaled Aerovant given twice daily for 12 weeks. The company licensed...
07:00 , Jul 6, 2009 |  BioCentury  |  Finance

Ebb & Flow

Historically, marketing of follow-on offerings has been a public process, while the selling of registered directs has been a private affair. But bankers have started structuring offerings that are a hybrid of the two types...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Company News

Aerovance board of directors update

Aerovance Inc. , Berkeley, Calif.   Business: Inflammation, Pulmonary   Appointed: Ann Hanham, a managing director at Burrill & Co.; and Alain Schreiber, a partner at ProQuest Investments   Departed: Hingge Hsu  ...
00:49 , Apr 8, 2009 |  BC Extra  |  Financial News

Aerovance raises $20 million

Aerovance Inc. (Berkeley, Calif.) raised $20 million in the first tranche of a planned $38 million private round led by new investor ProQuest Investments. BB Biotech Ventures, also a new investor, and existing investors Apax...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

Aerovant: Phase IIb started

Aerovance began the double-blind, placebo-controlled, dose-ranging, U.S. and European Phase llb AeroTrial trial to evaluate 1, 3 or 10 mg of inhaled Aerovant given twice daily for 12 weeks in about 500 patients. The company...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Company News

Aerovance management update

Aerovance Inc. , Berkeley, Calif.   Business: Inflammation, Pulmonary   Hired: Babatunde Otulana as SVP and CMO, formerly SVP of development and CMO at Aradigm Corp.  ...